Tides CDMO Services
With four major R&D platforms including peptides, oligonucleotides, high-performance liquid chromatography, and Tides analysis, the Porton Tides CDMO Services Platform is committed to providing integrated CMC solutions for global customers, covering all types of new drugs from pre-clinical to commercial.
100+
Customers
30+
Projects (IND/P1/P2/P3/NDA)
150+
Scientists
Our Services
Peptides
Linear Peptides (＜50 aa)
Cyclic Peptides (＜50 aa)
Peptide Modifications
Key RSMs and Intermediates
Oligonucleotides
ASO, siRNA
PMO
Aptamer
sgRNA
Oligo Modifications
Drug Delivery Materials
Ionizable Lipids/Cationic Lipids
Polymers for Drug Delivery
Complex/Conjugate Polysaccharides
Other Lipids
Linear Peptides (＜50 aa)
Cyclic Peptides (＜50 aa)
Peptide Modifications
Key RSMs and Intermediates
Molecular Type
- Linear Peptides (<50 aa)
- Cyclic Peptides (<50 aa)
- Arginine-rich Peptides
- Stapled Peptides
- Peptide Modifications: PEG, lipidation, N-methylation, etc.
- Key RSMs and Intermediates
- ADC Drug-Linker and PDC (OEB 5)
Technology
- Solid/Liquid/Hybrid Strategies Synthetic Solutions
- Combinate Downstream Technologies with Rp-prep-HPLC, Ionic Exchange, and TFF Technology
- Pre-formulation Development
- Comprehensive Analysis and Quality Research
Service Scope
- mg-g Scale Sample Preparation for Pre-clinical Studies
- Process Development and Scale-up Mfg. (non-GMP and GMP)
- Formulation Development and GMP Manufacturing
- Analytical Method Development, Validation, and Stability Study
- IND/NDA CMC Dossier
Service Mode
- Full Time Employee (FTE)
- Fee for Service (FFS)
ASO, siRNA
PMO
Aptamer
sgRNA
Oligo Modifications
Molecular Type
- 16~100 mer Oligonucleotides and Derivatives
- Modified Nucleotides
- Oligonucleotide Conjugates
- Custom Monomer
- Custom Galnac Derivatives
Technology
- Solid Phase Oligonucleotide Synthesis Technology Platform
- Ion Exchange, Ultrafiltration, Freeze-drying, and Other Purification and Post-processing Technologies
- Nucleic Acid Modification and Routine Injection Preparation Research and Development Capability (Including LNP)
- Comprehensive Analysis and Quality Research
Service Scope
- mg to g Scale Sample Preparation for Pre-clinical Studies
- Process Development and Scale-up Manufacturing (non-GMP and GMP)
- Formulation Development and GMP Manufacturing
- Analytical Method Development, Validation, and Stability Study
- IND/NDA CMC Dossier
Service Mode
- FTE (Full-Time Equivalent)
- FFS (Fee for Service)
Ionizable Lipids/Cationic Lipids
Polymers for Drug Delivery
Complex/Conjugate Polysaccharides
Other Lipids
Molecular Type
- Polymer-drug Conjugates, Dendrimers, Polypeptides
- Cationic/Ionizable Lipids, Peg-lipid, Phospholipids
- GalNAc Derivatives, Modified Monosaccharides, Synthetic Oligo[poly]saccharides
Technology
- Solid Phase and Liquid Phase Synthesis Technology Platform
- Combinate Downstream Technologies with prep-HPLC and Rp-prep-HPLC, Ionic Exchange, and TFF Technology
- Formulations Development and Manufacturing
- Comprehensive Analysis, Inspection and Quality Research
Service Scope
- mg-g Scale Sample Preparation for Pre-clinical Studies
- Process Development and Scale-up Mfg. (non-GMP & GMP)
- Analytical Method Development, Validation, and Stability Study
- IND/NDA CMC Dossier
Service Mode
Porton Sites
Minhang, Shanghai
Area: 20,000 ㎡
For mg-kg Scale Preparation, Process Development and Quality Research
Fengxian, Shanghai
Area: 64,000 ㎡
IND, Clinical Batches and Commercial Manufacturing
Testing, Release and Stability Study
Beibei, Chongqing
GMP Production Lines for Liquid Injection, Lyophilized Powder and Oral Preparations
Liquid Injection: 30-60 M Bottles/year
Lyophilized Powder: 6-12 M/year
Pudong, Shanghai
Area: 5,000+ ㎡
Bioconjugation (10-200 L, OEB 5)
Injectable Drug Product Development and Manufacturing
Analytical Platforms
Pre-clinical to Phase II
Case Studies
More
Preformulation Strategy- Inception to Completion
Drug discovery is an exceedingly complex process. Discovering a new chemical entity is in itself a huge accomplishment, which is often possible only after almost two decades of hard experimental work as well as advanced simulation efforts. Therefore, the next stage of the process, determination of toxicity becomes even more crucial as most new chemical entities (NCE) are disqualified if the NCE shows a potential toxic effect, despite any possible therapeutic effect.
More
Facilitating PROTAC Drugs Development with Innovative Processes
The PROTAC technology, through an innovative mechanism of "degradation rather than inhibition," provides a new pathway for targeting traditionally undruggable proteins and addressing resistance issues.
More
